Clinical trial
An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With…
NCT00042393 · Gilead Sciences, Industry · Approved for marketing
Key facts
| NCT number | NCT00042393 |
|---|---|
| Title | An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options |
| Official title | A Phase 3b, Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | Adefovir Dipivoxil |
| First posted | Aug 1, 2002 |
| Last update posted | Jan 7, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: